Mayflower Financial Advisors, LLC Gilead Sciences, Inc. Transaction History

Mayflower Financial Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 19, 2022	SELL	$59.54 - $68.01 $790,393 - $902,832	-13,275 Reduced 73.58%	4,767 $294,000
Q3 2022 Oct 17, 2022	BUY	$59.54 - $68.01 $794,739 - $907,797	13,348 Added 284.36%	18,042 $1.11 Million
Q2 2022 Jul 15, 2022	SELL	$57.72 - $65.01 $3,347 - $3,770	-58 Reduced 1.22%	4,694 $290,000
Q1 2022 Apr 21, 2022	SELL	$57.92 - $72.58 $50,853 - $63,725	-878 Reduced 15.6%	4,752 $283,000
Q4 2021 Jan 21, 2022	BUY	$64.88 - $73.64 $4,801 - $5,449	74 Added 1.33%	5,630 $409,000
Q3 2021 Oct 26, 2021	SELL	$67.69 - $73.03 $32,626 - $35,200	-482 Reduced 7.98%	5,556 $372,000
Q2 2021 Jul 29, 2021	BUY	$63.47 - $69.35 $190 - $208	3 Added 0.05%	6,038 $416,000
Q1 2021 Apr 23, 2021	SELL	$60.0 - $68.46 $360 - $410	-6 Reduced 0.1%	6,035 $390,000
Q4 2020 Apr 12, 2021	BUY	$56.65 - $64.55 $342,222 - $389,946	6,041 New	6,041 $352,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Mayflower Financial Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Mayflower Financial Advisors, LLC with notifications on news.